Lupin to Present Phase 1 Data on PRMTS5 Inhibitor LNP7457 at ASCO Annual Meeting 2025

Global pharma major Lupin Limited will present data from its Phase 1a clinical trial evaluating LNP7457, a PRMTS5 inhibitor, at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois, from May 30 to June 3, 2025. The study found LNP7457 to be generally safe and well tolerated in patients with advanced or metastatic solid tumors, with a desirable PK/PD profile and no impact of food on the pharmacokinetics. Lupin will continue to study the efficacy of LNP7457 in its phase 1b trial in India and explore its potential for treatment of cancers with significant unmet medical needs.